200 related articles for article (PubMed ID: 23868281)
21. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.
Bosch TM
Methods Mol Biol; 2008; 448():63-76. PubMed ID: 18370231
[TBL] [Abstract][Full Text] [Related]
22. Is (+)-[13C]-pantoprazole better than (±)-[13C]-pantoprazole for the breath test to evaluate CYP2C19 enzyme activity?
Thacker DL; Modak A; Flockhart DA; Desta Z
J Breath Res; 2013 Mar; 7(1):016001. PubMed ID: 23257668
[TBL] [Abstract][Full Text] [Related]
23. Pharmacogenetics in cancer etiology and chemotherapy.
Boddy AV; Ratain MJ
Clin Cancer Res; 1997 Jul; 3(7):1025-30. PubMed ID: 9815780
[No Abstract] [Full Text] [Related]
24. Pharmacogenetics and cancer chemotherapy.
Iyer L; Ratain MJ
Eur J Cancer; 1998 Sep; 34(10):1493-9. PubMed ID: 9893619
[TBL] [Abstract][Full Text] [Related]
25. Stereoselective pharmacokinetics of stable isotope (+/-)-[13C]-pantoprazole: Implications for a rapid screening phenotype test of CYP2C19 activity.
Thacker DL; Modak A; Nguyen PD; Flockhart DA; Desta Z
Chirality; 2011 Nov; 23(10):904-9. PubMed ID: 21935988
[TBL] [Abstract][Full Text] [Related]
26. Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication.
Karaca RO; Kalkisim S; Altinbas A; Kilincalp S; Yuksel I; Goktas MT; Yasar U; Bozkurt A; Babaoglu MO
Basic Clin Pharmacol Toxicol; 2017 Feb; 120(2):199-206. PubMed ID: 27611887
[TBL] [Abstract][Full Text] [Related]
27. (13)C breath tests in personalized medicine: fiction or reality?
Modak AS
Expert Rev Mol Diagn; 2009 Nov; 9(8):805-15. PubMed ID: 19895226
[TBL] [Abstract][Full Text] [Related]
28. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity.
Ciccolini J; Mercier C; Blachon MF; Favre R; Durand A; Lacarelle B
J Clin Pharm Ther; 2004 Aug; 29(4):307-15. PubMed ID: 15271097
[TBL] [Abstract][Full Text] [Related]
29. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
[TBL] [Abstract][Full Text] [Related]
30. Genetic determinants of cancer drug efficacy and toxicity: practical considerations and perspectives.
Candelaria M; Taja-Chayeb L; Arce-Salinas C; Vidal-Millan S; Serrano-Olvera A; Dueñas-Gonzalez A
Anticancer Drugs; 2005 Oct; 16(9):923-33. PubMed ID: 16162969
[TBL] [Abstract][Full Text] [Related]
31. Physiologically based pharmacokinetic modelling of the three-step metabolism of pyrimidine using C-uracil as an in vivo probe.
Ito S; Kawamura T; Inada M; Inoue Y; Hirao Y; Koga T; Kunizaki J; Shimizu T; Sato H
Br J Clin Pharmacol; 2005 Dec; 60(6):584-93. PubMed ID: 16305582
[TBL] [Abstract][Full Text] [Related]
32. Dihydropyrimidine dehydrogenase in the metabolism of the anticancer drugs.
Sharma V; Gupta SK; Verma M
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1157-1166. PubMed ID: 31482228
[TBL] [Abstract][Full Text] [Related]
33. Metabolism of cytochrome P4503A substrates in vivo administered by the same route: lack of correlation between alfentanil clearance and erythromycin breath test.
Krivoruk Y; Kinirons MT; Wood AJ; Wood M
Clin Pharmacol Ther; 1994 Dec; 56(6 Pt 1):608-14. PubMed ID: 7995002
[TBL] [Abstract][Full Text] [Related]
34. [Detection of dihydropyrimidine dehydrogenase deficiency before treatment by fluoropyrimidines].
Gamelin E; Boisdron-Celle M; Morel A
Therapie; 2007; 62(2):99-103. PubMed ID: 17582309
[TBL] [Abstract][Full Text] [Related]
35. The erythromycin breath test for the prediction of drug clearance.
Rivory LP; Slaviero KA; Hoskins JM; Clarke SJ
Clin Pharmacokinet; 2001; 40(3):151-8. PubMed ID: 11327195
[TBL] [Abstract][Full Text] [Related]
36. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?
Meulendijks D; Cats A; Beijnen JH; Schellens JH
Cancer Treat Rev; 2016 Nov; 50():23-34. PubMed ID: 27589829
[TBL] [Abstract][Full Text] [Related]
37. Changes in CYP2C19 enzyme activity evaluated by the [(13)C]-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity.
Harvey A; Modak A; Déry U; Roy M; Rinfret S; Bertrand OF; Larose É; Rodés-Cabau J; Barbeau G; Gleeton O; Nguyen CM; Proulx G; Noël B; Roy L; Paradis JM; De Larochellière R; Déry JP
J Breath Res; 2016 Jan; 10(1):017104. PubMed ID: 26815196
[TBL] [Abstract][Full Text] [Related]
38. Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism.
Rochat B
Clin Pharmacokinet; 2005; 44(4):349-66. PubMed ID: 15828850
[TBL] [Abstract][Full Text] [Related]
39. Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin.
Paine MF; Wagner DA; Hoffmaster KA; Watkins PB
Clin Pharmacol Ther; 2002 Nov; 72(5):524-35. PubMed ID: 12426516
[TBL] [Abstract][Full Text] [Related]
40. Endogenous plasma and salivary uracil to dihydrouracil ratios and DPYD genotyping as predictors of severe fluoropyrimidine toxicity in patients with gastrointestinal malignancies.
Galarza AF; Linden R; Antunes MV; Hahn RZ; Raymundo S; da Silva AC; Staggemeier R; Spilki FR; Schwartsmann G
Clin Biochem; 2016 Nov; 49(16-17):1221-1226. PubMed ID: 27399164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
